Promising combo for rare sarcoma shows early safety
NCT ID NCT02787642
First seen Feb 26, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This early-phase study tested a drug called olaparib together with radiation therapy for people with advanced soft-tissue sarcoma that couldn't be removed by surgery. The main goal was to find the safest dose of olaparib and see how many patients had serious side effects. A total of 41 adults took part, and the results help guide future research on this combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Léon Bérard
Lyon, 69373, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Claudius Regaud - IUCT
Toulouse, 31052, France
-
Institut du Cancer de Montpellier
Montpellier, 34298, France
Conditions
Explore the condition pages connected to this study.